ALNY Down Despite Positive Data From Heart Disease Drug Study - Fulcrum Therapeutics ( NASDAQ:FULC ) , Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Shares of Alnylam Pharmaceuticals, Inc. ALNY were down 8.5% on Aug. 30, after the company announced detailed data from the phase III HELIOS-B, which evaluated its investigational RNAi therapeutic, Amvuttra ( vutrisiran ) for an expanded indication.
| Ticker |
Sentiment |
Impact |
|
ALNY
|
Neutral
|
12 %
|
|
KRYS
|
Somewhat Bullish
|
23 %
|
|
ILMN
|
Somewhat Bullish
|
17 %
|
|
FULC
|
Neutral
|
23 %
|
